Japan approved iPS cells for the treatment of Parkinson's disease clinical trial
August 01, 2018 Source: Science and Technology Daily
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];According to the official website of the US Science magazine, Japanese researchers announced on the 30th to launch a clinical trial to treat Parkinson's disease with neurogenic substances derived from induced pluripotent stem cells (iPS). iPS is a mature cell that has been chemically restored to the early stages of development. In theory, it can differentiate into any cell in an adult.
Neurosurgeon Takahashi, the neurosurgeon of the iPS Cell Research and Application Center (CiRA) at Kyoto University, will work with Kyoto University Hospital to carry out this work. The current plan is to obtain dopaminergic progenitor cells from iPS cells (which can develop into neurons, produce dopamine, and directly enter brain regions that play a key role in neurodegeneration associated with Parkinson's disease) and inject them into patients. The putamen (in the circular structure at the base of the forebrain). The surgeon will drill two small holes in the patient's skull and inject about 5 million cells using a special device.
The Takahashi Shield team reported last year that the symptoms of the Parkinson's disease monkey model showed significant signs of improvement after injection of neurons prepared from human iPS cells for two years. Parkinson's disease is caused by the death of specialized cells that produce the neurotransmitter dopamine in the brain. Lack of dopamine leads to decreased motor skills, difficulty walking and involuntary tremors. As the disease worsens, it can lead to dementia.
CiRA does not make different iPS cells for different patients, but instead acquires iPS cells from healthy donors with specific cells that are less likely to cause immune rejection. Citro's director and Nobel laureate Yamanaka said: "Using cell reserves can be done faster and more economically." As an additional precaution, patients will receive a common immunosuppressant along with progenitor cells.
This is the third human iPS cell therapy human trial approved in Japan. The patient was recruited at 5 pm local time on the 30th, and plans to recruit 7 people and track it for 2 years after the injection.
The first two human trials were initiated in 2014 using iPS cells to treat age-related macular degeneration (AMD), led by Takahashi Yasushi of the Center for Developmental Biology, Japan Institute of Physical and Chemical Sciences; earlier this year, Osaka University's iPS-based Cellular ischemic heart disease studies have been conditionally approved. (Liu Xia)
Tourmaline heating mat,Jade mattress,Natural jade and tourmaline mat,Tourmaline infrared heat mat
Guangzhou Fuerle Health Technology Co., Ltd , https://www.fuerlegroup.com